1 completed, 1 terminated. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Terminated 1 |
| Phase 2 | 1 | Completed 1 |
Follow Genticel: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Tolerability, and Immunogenicity of GTL001 Vaccine Adjuvanted With Imiquimod Cream in HPV 16- and/or HPV 18-Infected Women Aged 25 to 65 Years, With Normal Cytology, ASCUS, or LSIL GTL001+, Aldara - HPV 16- and/or HPV 18-Infected Women With Normal Cytology, ASCUS, or LSIL | Phase 1 | Terminated | Genticel | 13 | 2015-08-01 | 2016-12-02 |
| Phase II Study of HPV Therapeutic Vaccine in HPV Infected Women With Normal Cytology or ASCUS/LSIL ProCervix, Placebo - Genital Infection Viral, HUMAN PAPILLOMA VIRUS | Phase 2 | Completed | Genticel | 239 | 2013-12-01 | 2016-12-02 |
Atypical Squamous Cells of the Cervix (1)
Imiquimod (1)
Belgium (1) · Finland (1) · France (1) · Germany (1) · Netherlands (1) · Spain (1) · United Kingdom (1) · United States (1)